Assessment of the clinical effect of topical tacalcitol on ichthyoses with retentive hyperkeratosis.
BACKGROUND
Topical tacalcitol (1alpha,24-dihydroxyvitamin D3) has been demonstrated to produce beneficial clinical effects on epidermo-hyperproliferative disorders such as psoriasis and pityriasis rubra pilaris. However, the efficacy of the agent has not been elucidated in retentive hyperkeratotic disorders.


OBJECTIVE
The object of the study was to assess the clinical efficacy of topical tacalcitol against ichthyoses with retentive hyperkeratosis; X-linked ichthyosis (XLI), ichthyosis vulgaris (IV), and acquired ichthyosis (AI).


METHODS
Tacalcitol was topically applied on 9 patients with the retention ichthyoses, using a single-blinded, bilaterally paired approach with right-left comparison of tacalcitol and the base.


RESULTS
Clinical improvement obtained by topical tacalcitol exclusively was not superior to that of the vehicle alone in any of the ichthyotic patients.


CONCLUSIONS
Topical tacalcitol therapy was ineffective against ichthyoses without epidermal hyperproliferation.
Okano
M
M
Department of Dermatology, Aizembashi Hospital, Osaka, Japan.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002648:Child; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004100:Dihydroxycholecalciferols / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007057:Ichthyosis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D016112:Ichthyosis Vulgaris / Q000473:pathology; D016114:Ichthyosis, X-Linked / Q000473:pathology; D007642:Keratosis / Q000150:complications*; D008297:Male; D008875:Middle Aged
D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D004100:Dihydroxycholecalciferols; C023850:1 alpha,24-dihydroxyvitamin D3